SRSathishKumar Ramaswamy

SathishKumar Ramaswamy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


SathishKumar Ramaswamy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery of bioactive compounds from medicinal plants: insights into Wrightia tinctoria as a potential antistaphylococcal agent targeting clumping factor A

    by Vidya S. L., Anantha Bhairavi V., R. Sathishkumar

    Staphylococcus aureus, a major human pathogen, exhibits strong survival abilities both inside and outside host cells. The increasing prevalence of antibiotic-resistant strains presents a major challenge to modern medicine. Bioactive compounds from medicinal plants represent a potential alternative, owing to their diverse secondary metabolites. This study employed in silico docking and molecular dynamics simulations to identify bioactive compounds from medicinal plants targeting the virulence protein clumping factor A (ClfA) of S. aureus. Phytocompounds from Breynia retusa, Hemigraphis alternata, Imperata cylindrica, Oldenlandia corymbosa, Sida rhombifolia, Scoparia dulcis, Tephrosia purpurea, and Wrightia tinctoria were screened for pharmacokinetic properties, followed by molecular docking and dynamics simulations. Indirubin from W. tinctoria exhibited strong binding affinity for ClfA, with stable interactions confirmed by molecular dynamics simulations. Antibacterial assays using fresh and dry W. tinctoria leaf extracts demonstrated significant inhibition of S. aureus. GC–MS analysis identified 50 bioactive compounds, further supporting the plant’s potential as a natural antimicrobial source. These findings highlight W. tinctoria, particularly indirubin as a promising candidates for developing anti-staphylococcal and wound-healing agents, warranting further in vivo validation.

  • IN SILICO IDENTIFICATION OF NOVEL BIOACTIVE COMPOUNDS FROM MEDICINAL PLANTS AGAINST DIABETIC FOOT ULCER

    by Sonesh Kumar K, Sarah Di Souza, Anantha Bhairavi V, Sathishkumar R

    Diabetes mellitus is a chronic lifestyle disease with imbalanced insulin levels in patients, resulting in adverse conditions like renal failure, blindness, heart attack and stroke. Diabetic foot ulcers are the most dangerous complication characterised by a pathological triad of infection and vascular disease in the foot. The lower leg of a diabetic patient is more susceptible to infection, resulting in foot ulcers, which, when kept untreated, necessitates leg amputation. Human fibroblast collagenase is a key protein often required in small quantities for wound healing. However, they are imbalanced in diabetic foot ulcers, causing deterioration and inability to heal. Although drugs are available, higher dosages promote gastrointestinal issues with nausea, diarrhoea and stomach pain. The current study fully anticipates identifying a prominent herbal drug to treat diabetic foot ulcers using Bioinformatic tools. The study revealed that phytocompounds from Ficus carica exhibited excellent binding with the target, suggesting their well-known ability to treat diabetic foot ulcers.

  • Open Access

    Identification of effective plant extracts against candidiasis: an in silico and in vitro approach

    by V. Anantha Bhairavi, S. L. Vidya, R. Sathishkumar

    Background: Globally, millions of people suffer from repeated fungal infections affecting the skin, keratinized tissues, and mucosal membranes. Approximately 1.7 million cases result in death with an elevated incidence rate among immunocompromised people that may later result in severe infections. Among the causative agents, Candida albicans are the most prevalent fungi inducing subcutaneous to invasive candidiasis. Although they are commensals in human body alteration in gut or prolonged treatments results in candidiasis. Several virulence proteins of C. albicans are involved in infections and secreted aspartic proteases2 (SAP2) plays an important role among them by causing damage to the reconstituted human epithelium. In the present study, phytochemicals from Heliotropium indicum, Grona triflora, Ziziphus mauritiana, Atalantia racemosa, Coccinia grandis, Caryota urens, Aristolochia bracteolata, Evolvulus alsinoides, Pyrus communis and Commelina benghalensis were studied against SAP2 with the help of bioinformatic tools to understand their binding efficiency. Results: The phytochemical structures were retrieved from PubChem database and the target protein structure was retrieved from PDB database with ID:3PVK. ADME profiling for phytochemicals was performed with Qikprop module, followed by docking with protein using Schrodinger software. Docking studies showed that Indicine-N-Oxide from H. indicum scored the significant glide score of − 5.54 kcal/mol. Finally, antifungal studies against C. albicans were conducted using several extracts of plants containing phytochemicals with considerable glide scores on docking studies. The Ethyl acetate leaf extract of H. indicum prominently inhibited the fungal growth when compared with the control. Conclusion: Identification of effective therapeutic candidates for the treatment of fungal infection is facilitated by the potential of H. indicum to hinder fungal growth and the interaction of their phytocompounds with fungal targets paves a way for developing a novel drug.


  • A scientific pharmacognosy on Gaucher’s disease: an in silico analysis

    by Amritha Pozhaiparambil Sasikumar, SathishKumar Ramaswamy, Sreeram Sudhir

    From ancient times, studies on herbal medicine and pharmacognosy have increased gradually worldwide, due to the increased side effects, adverse drug reactions, and charge lines of modern medicines. Plants are well known for their medicinal effects and nutritional values. They contain bioactive compounds which display a wide spectrum of therapeutic effects. Gaucher’s disease (GD) is a rare autosomal recessively inherited metabolic disorder caused due to the defect in Glucosylceramidase beta gene coding for the enzyme acid-β-glucosidase in humans. We revealed the profound binding efficiency of five selected bioactive compounds from different plants against the main enzyme acid-β-glucosidase responsible for GD through molecular docking. An in silico approach along with the ADMET profiles of phytocompounds was done using the Schrodinger software. The preventive measure of GD leads to side effects, inaccessible and unaffordable which put forth the emergence of phytocompounds which have fewer toxic effects, and one such compound is β-D-Glucopyranose with the best docking score (–10.28 kcal/mol) and an excellent binding affinity than other ligands, which could be further analyzed for stability using molecular dynamics study and in vitro. Being a dietary supplement, these compounds could be prepared in any form of formulation as a drug.


  • Targeting the ENV spike protein of HIV with naturally occurring compounds: an in-silico study for drug designing

    by S. Sreeram, R. Sathishkumar, P. S. Amritha

    Human Immunodeficiency Virus (HIV) infects human by destroying the immune system. The types of HIV strains HIV-1 and HIV-2, among HIV-1 being more prevalent and considered deadly. Eventually either of the strains leads to disease Acquired Immunodeficiency Syndrome (AIDS). Traditional medicinal plants have a pivotal role in the modern pharmacological process due to their rich composition of secondary metabolites with significant biological activity. Computational tools are gaining momentum as they predict with higher accuracy, robust and provide insight in the interaction of small molecule with the disease target protein. This study was conducted for understanding the interaction mode of Phyto compounds with Env spike proteins of HIV. The compounds are studied for ADME properties and molecular docking using Schrödinger software was performed. From the results, Ethyl gallate was observed with least docking score and higher binding affinity for HIV-ENV protein (4CC8) and Cinnamyl acetate (cis/trans) with HIV-1-ENV protein (6ULC).